The Impact of Sequencing and Cytogenetics on Diagnostics

The ability to read the human genome — first achieved at enormous cost and effort over more than a decade — has been transformed into a routine clinical tool in just two decades. Today, DNA sequencing and cytogenetic analysis are at the heart of modern diagnostics, enabling precise identification of genetic conditions that were previously undetectable or took years to diagnose.

What Is Cytogenetics?

Cytogenetics is the study of chromosomes — their structure, number, and behavior. Classical cytogenetic techniques analyze chromosomes under a microscope, while modern molecular cytogenetics uses DNA probes and sequencing to detect chromosomal abnormalities at much higher resolution.

Key Cytogenetic Techniques

• Karyotyping: The traditional method of visualizing all 46 chromosomes. Detects large chromosomal abnormalities (trisomies, monosomies, large deletions, translocations). Resolution: ~5–10 Mb.
• FISH (Fluorescence In Situ Hybridization): Uses fluorescent DNA probes to detect specific chromosomal regions. Useful for detecting specific known abnormalities (e.g., BCR-ABL in CML, HER2 amplification in breast cancer). Resolution: ~100–200 kb.
• Chromosomal Microarray (CMA): Detects copy number variants (CNVs) — deletions and duplications — across the entire genome simultaneously. Resolution: ~1–10 kb. Now the first-line test for developmental delay, intellectual disability, and autism spectrum disorder.

DNA Sequencing in Diagnostics

Sanger Sequencing

The gold standard for sequencing specific genes or confirming variants identified by other methods. Highly accurate but limited to small genomic regions. Used for confirmatory testing and family studies.

Next-Generation Sequencing (NGS)

NGS technologies can sequence millions of DNA fragments simultaneously, enabling analysis of entire genes, gene panels, exomes, or genomes in a single test.

• Gene panels: Targeted sequencing of a defined set of genes associated with a specific condition or group of conditions. Cost-effective for conditions with known genetic causes.
• Whole Exome Sequencing (WES): Sequences all protein-coding regions of the genome (~1–2% of total genome, containing ~85% of known disease-causing mutations). Diagnostic yield of 25–40% for patients with suspected genetic conditions.
• Whole Genome Sequencing (WGS): Sequences the entire genome, including non-coding regions. Higher diagnostic yield than WES for complex cases. Increasingly used as costs decline.

Clinical Applications

Rare Disease Diagnosis

WES and WGS have transformed rare disease diagnosis, reducing the diagnostic odyssey from an average of 4–7 years to months in many cases. For children with unexplained developmental delay, intellectual disability, or multiple congenital anomalies, WES has a diagnostic yield of 25–40%.

Cancer Diagnostics

Comprehensive genomic profiling of tumor tissue identifies actionable mutations that guide targeted therapy selection. Liquid biopsy (cell-free DNA sequencing from blood) enables non-invasive tumor monitoring and early detection of resistance mutations.

Prenatal Diagnosis

Chromosomal microarray has replaced karyotyping as the first-line prenatal diagnostic test for structural anomalies detected on ultrasound. NIPT uses cell-free fetal DNA sequencing for non-invasive chromosomal screening.

Pharmacogenomics

Sequencing of drug-metabolizing enzyme genes (CYP2D6, CYP2C19, CYP2C9) guides medication selection and dosing across multiple therapeutic areas.

FAQs

What is the difference between WES and WGS?

WES sequences only the protein-coding regions (exons), which contain ~85% of known disease-causing mutations. WGS sequences the entire genome, including non-coding regions. WGS has higher diagnostic yield but is more expensive and generates more data requiring interpretation.

How long do sequencing results take?

Gene panels typically return results in 2–4 weeks. WES results typically take 4–8 weeks. WGS may take 6–12 weeks. Urgent clinical situations may have expedited turnaround times.